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SumlTlary 
Interleukin  (IL)  12 is a proinflammatory cytokine produced by phagocytic cells,  B  cells,  and 
other antigen-presenting ceils that modulates adaptive immune responses by favoring the gen- 
eration ofT helper type 1 cells. IL-12 mediates some of its physiological activities by acting as a 
potent inducer of interferon (IFN) y  production by T  and natural killer cells.  IFN-y enhances 
the  ability  of the  phagocytic  cells  to  produce  IL-12  and  other  proinflammatory cytokines. 
Thus, IL-12-induced IFN-y acts in a positive feedback loop that represents an important am- 
plifying mechanism in  the  inflammatory response to  infections.  We  show  here  that  IFN-~/ 
enhances IL-12 production mostly by priming phagocytic cells  for lipopolysaccharide (LPS)- 
induced transcription of the IL-12 p40 gene, which encodes the heavy chain of the IL-12 het- 
erodimer;  furthermore,  IFN-y directly induces  transcription  of the  IL-12 p35  gene,  which 
encodes the light chain of IL-12, and has at least an additive effect with LPS stimulation in in- 
ducing its transcription. The priming effect of IFN-y on the LPS-induced p40 gene transcrip- 
tion requires preincubation of the cells with IFN-~/for at least 8 h  to obtain a maximal effect. 
The priming effect of IFN-~/for IL-12 production is predominantly at the transcriptional level 
for both the p40 and the p35 gene, and no evidence for a major role of posttranscriptional or 
translational  mechanisms was  found.  A  3.3-kb  human  IL-12 p40  promoter construct  trans- 
fected into cell lines recapitulated the tissue specificity of the endogenous gene, being silent in 
two human T  cell lines, constitutively active in two human Epstein-Barr virus-positive B lym- 
phoblastoid cell lines, and LPS inducible in the human THP-1 and mouse RAW264.7 mono- 
cytic cell lines. Because the RAW264.7  cell line is easily transfectable and regulates the endog- 
enous IL-12 p40 gene in response to IFN-y or LPS similarly to human monocytes, it was used 
for analysis  of the regulation of the cloned human IL-12 p40 promoter. A requirement for the 
region between  -222  and  -204  in both LPS responsiveness and IFN-'y priming was estab- 
lished. This region contains an ets consensus sequence that was shown to mediate activation of 
the promoter by IFN-y and LPS, as well as by a cotransfected ets-2. The -222 construct was 
also  regulated  in  a  tissue-specific  manner.  Two  other  elements,  IRF-1  located  at  -730  to 
-719, and NF-IL6 at -520 to -512, were also studied by deletion analysis, which did not re- 
sult in decreased response to IFN-y and LPS stimulation. 
N 
'K cell stimulatory factor or IL-12 is a heterodimer of 
70,000  daltons  (p70)  formed  by  two  covalently 
linked  glycosylated chains  of r  (p40)  and  35,000 
(p35) daltons (1).  IL-12 is produced by phagocytic cells, B 
cells,  and  other  types of APC  (2).  IL-12 mediates several 
biological activities on T  and NK cells, including induction 
of IFN-y production, enhancement of cell-mediated cyto- 
toxicity, and mitogenic effects (1). Through these functions 
IL-12 plays a major role in the early inflammatory response 
to infections. In addition, APC-produced IL-12 is critically 
involved in  the  generation  of Thl  cells  (3-9)  and  is  re- 
quired  for optimal differentiation of CTL (10).  The  early 
decision toward Thl  or Th2 ceils in the immune response 
is dependent  on the balance between IL-12, which favors 
Thl responses, and IL-4, which favors Th2 responses (11). 
Originally,  IL-12 was  found  to  be  produced  by EBV- 
transformed human B  cell lines  either constitutively or in 
response to phorbol diesters  (1,  12).  However,  the  major 
producer  cells  of IL-12  are  phagocytic  cells  (monocytes, 
macrophages,  or  neutrophils),  which  do  not  respond  to 
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efficient  inducers  of  IL-12  production  from  phagocytic 
cells are bacteria, bacterial products, and intracellular para- 
sites (2). The genetic control of the production of IL-12 is 
complex because of the requirement for expression of two 
different  genes  to  produce  the  biologically  active  het- 
erodimer. The expression of p40 transcripts is highly corre- 
lated with the ability of the producer cells to make IL-12, 
whereas  the  p35  transcripts  are  ubiquitously  expressed in 
almost all cell types of both hematopoietic and nonhemato- 
poietic origin (2,  14). As originally observed in B  cell lines, 
stimulated  PBMC  and  neutrophils  produce  the  free  p40 
chain in a  10- to 50-fold excess over the biologically active 
p70  heterodimer  (2,  13).  Both  p40  and  p35  messenger 
RNAs  (mRNAs)  are constitutively expressed at very low 
levels in unstimulated PBMC  and neutrophils. Accumula- 
tion of both is upregulated by stimulation with bacteria or 
bacterial products, although the induction of the p40  gene 
is  much  more  marked,  resulting in  an  abundance  of p40 
transcripts  in  stimulated  cells up  to  200-fold  higher  than 
that of p35  transcripts, which may explain the excess pro- 
duction of the p40 chain (2,  13,  15). 
The ability of phagocytic cells to produce IL-12 is regu- 
lated by several cytokines with activating or suppressing ef- 
fects on  the producer cells.  IFN-3~ and  GM-CSF,  among 
other  cytokines,  enhance  the  production  of IL-12  from 
phagocytic  cells  (13,  15,  16  and  our  unpublished  data), 
whereas IL-10, IL-4, IL-13, and TGF-[3 inhibit IL-12 pro- 
duction (16,  17).  The latter inhibit both IL-12 protein se- 
cretion  and  p40  and p35  mRNA  accumulation in  stimu- 
lated  phagocytic  cells.  However,  the  effect  of IL-4  and 
IL-13  is  complex:  They  inhibit production  of IL-12  and 
TNF-cx  when  added to  monocytes  simultaneously to  the 
inducing stimulus but prime the monocytes for IL-12 pro- 
duction  in response to various stimuli when  added to  the 
culture at least 18 h before the stimulus (17). 
In this report,  we  show  that p40  and p35  are differen- 
tially  regulated  by  IFN-'y  and  LPS  in  PBMC;  that  is, 
IFN-~/treatment does not directly induce p40 gene expres- 
sion and protein production, but it primes monocytic cells 
to  produce  them  in  response  to  LPS  stimulation.  On  the 
other hand, IFN-y alone can induce low levels of p35 tran- 
scription and rnRNA  accumulation.  Treatment  of mono- 
cytic  cells  with  IFN-',/  before  LPS  stimulation  enhances 
transcription rates,  steady-state mRNA  accumulation,  and 
protein synthesis synergistically for p40  and  additively for 
p35.  The  priming effect of IFN--/ on  IL-12  expression is 
primarily at  the  transcriptional level.  Finally, we  demon- 
strate that the cloned human p40 promoter can recapitulate 
the  behavior  of its  endogenous  counterpart  in  transient 
transfection assays in terms  of cell type specificity and  re- 
sponsiveness to IFN-~ and LPS. 
Materials  and Methods 
Production  and  Quantitation  of IL-I2.  PBMC  were  isolated 
from four normal donors by Ficoll gradient (Accu-prep lympho- 
cytes; Accurate Chemical & Scientific Corp., Westbury, NY) and 
cultured in RPMI-1640  medium supplemented with  10%  FCS 
(Irvine Scientific, Santa Ana,  CA), both  endotoxin free,  at  106 
cells/ml in  1 ml of culture. After 18  h,  cells were treated with 
nothing or with recombinant human  (rh) 1 IFN-',/ (1,000  U/ml) 
for 24, 16, or 8 h before and simultaneously with (0 h) LPS (1 p~g/ 
ml) stimulation for 30 h. Control cultures were treated with IFN-~ 
alone or LPS alone. Culture supematants were collected and used 
for detection of IL-12 p40 and p70 in an RIA that detects both 
free p40  and p40 bound to p35  in the heterodimeric form  (2). 
The  human  p70  heterodimer was  detected using an ELISA kit 
(Quantikine Human IL-12 Immunoassay, D1200; R&D Systems, 
Inc., Minneapolis, MN) according to the manufacturer's instruc- 
tions. 
Reagents.  Human  IFN-~ was purchased from Genzyme Di- 
agnostics (Cambridge, MA). Murine IFN-',/ was  a generous gift 
from  Dr.  Gianni  Garrotta  (Human  Genome  Sciences,  Inc., 
Rockville, MD).  LPS was purchased from Sigma Chemical Co. 
(St. Louis, MO). 
Immunoprecipitation of lL-12 p40 and p 70from Human Monocytes. 
PBMC depleted of T  cells by rosetting with SRBC treated with 
AET were incubated with medium alone or with rhlFN-3, (1,000 
U/ml).  After  24  h,  cells  were  washed  with  methionine-free 
RPMI-1640 medium and resuspended in 2 ml of the same me- 
dium containing 10% fetal bovine serum and 0.5  mCi  [35S]me- 
thionine.  Cells  preincubated  with  medium  were  treated  with 
medium alone or with LPS (1  p~g/ml), and cells pretreated with 
IFN-~/were treated with IFN-',/ (1,000  U/rnl) or IFN-~/ (1,000 
U/ml) plus LPS (1 txg/ml). Supernatants (2 ml) were collected af- 
ter 18 h, diluted with  1 ml ofTBS/NP-40  1%/BSA 0.5%  con- 
taining leupeptin  and  antipain  as  protease  inhibitors, and  pre- 
cleared once with 1 txg of irrelevant mAb and three times with 50 
txl Sepharose-protein A (overnight at 0~  Each sample was then 
treated with  10  Ixl of anti-human  p40  mAb C11.79  bound to 
CNBr-activated Sepharose (2 mg mAb/ml Sepharose) for 90 rain 
at  0~  Immunoprecipitated materials were  washed  four  times 
with 1 ml of 0.1% TBS/NP-40 and twice with l  ml of0.1% NP- 
40. Immunoprecipitates were eluted by boiling samples for 3 rain 
with 40 btl of 2.3% SDS (Laemmli buffer) in nonreducing condi- 
tions. All 40-btl samples were run on a 10% SDS-polyacrylamide 
gel. The gel was dried and exposed in a Phosphorlmager screen 
(Molecular Dynamics, Inc., Sunnyvale, CA) for 72 h. 
Production of lL- 12 by the Murine Cell Line RA W264.7.  Mouse 
macrophagic cell line RAW264.7 (American Tissue Culture Col- 
lection [ATCC], Rockville, MD) was cultured in the same con- 
ditions and time course as the PBMC,  except that the cells were 
pretreated with 1.2% DMSO 24 h before LPS induction, because 
DMSO treatment enhances the abili  W of human and murine my- 
eloid cell lines to produce IL-12  (16),  and recombinant murine 
(rm) IFN-~/was used. p40 was then measured using an RIA spe- 
cific for murine p40 (18). The coating antibody used was C17.15, 
and the 12SI-labeled detection antibody was C15.6. 
Electroporation.  Murine  macrophagic  cell  line  RAW264.7, 
the  human  B  cell lines RPMI-8866  and CESS,  and the T  cell 
lines Molt 13 and Jurkat were grown to confluence (106/ml)  in 
RPMI-1640  medium supplemented with  10% FCS. Cells were 
transfected with the 3.3-kb p40 promoter-reporter construct or 
other  constructs  (see  below)  prepared by  the  CsC1 procedure. 
Cells were  collected, washed  once  with  RPMI-1640  medium, 
and resuspended in the same medium at a concentration of 30 X 
1Abbreviations used in this  paper: IRF, IFN-regulatory factor; mRNA, mes- 
senger RNA; NO, nitrous oxide; rh, recombinant human; m~, recombi- 
nant routine; TPA, tetradecanoylphorbo113-acetate. 
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(24 Ixg p40-1uc/3.3 kb, 6 Izg CMV-13-galactosidase, 270 Dg BS/ 
KSII  +)  were  placed in 0.45-cm  electroporation cuvettes  (Gene 
Pulser; Bio-P,.ad Laboratories, Richmond, CA), and electropora- 
tion was carried out at 960 IxF and 400 V. Transfected cells were 
collected and resuspended to 5 ￿  106/ml in RPMI-1640  +  10% 
FCS, and chloroquine was added to a final concentration of 10 
p~M. Cells were placed in wells (2 ml/well) of a 24-well plate and 
incubated for 16 h at 37~  in a 5% CO2 atmosphere. Cells were 
treated with 1.2% DMSO for 24 h and with rmlFN-y (1,000  U/ 
ml) for 24,  16,  8,  or 0 h before the addition of LPS (1  I*g/ml). 
After an 8-h stimulation with LPS, cells were harvested and lysed 
by Triton  and  freeze-thawing.  Lysates  were  used  for both  lu- 
ciferase and [3-galactosidase assays. 
DEAE-Dextran  Transfection.  THP-1  cells  (ATCC)  were 
grown to confluence (106/ml) in RPMI-1640 supplemented with 
20% FCS and transfected with the 3.3 kb p40 promoter-reporter 
construct by the DEAE-dextran method. THP-1  cells were re- 
suspended  to  106  cells/ml in  R.PMI-1640  containing  50  mM 
Tris,  pH 7.3,  and 20  ml of suspension for each condition was 
placed in T-25 flasks. To each flask, 40 Dg of plasmid DNA (20 
D1 p40-1uc/3.3 kb, 8 btl CMV-[3-galactosidase, 12 btl BS/KSII  +) 
and 50  p~l of sterile 100  mg/ml DEAE-dextran were added and 
gently shaken to ensure even distribution. Flasks were incubated 
for 1 h at 37~  Cells were then collected, spun at 1,500  rpm for 
5 rain, washed once with 20 ml of RPMI-1640 containing 100 
mM (1.5 U/ml) heparin, and washed twice more with 20 ml of 
R.PMI-1640.  Cells were resuspended to a  concentration of 106 
cells/ml in RPMI-1640 supplemented with 20% FCS, distributed 
at 10 ml per flask, and incubated for 18 h at 37~  in a 5% CO2 at- 
mosphere. Cells were treated with 1.2% DMSO for 16 h before 
LPS (1 txg/ml) induction for 8 h. After LPS induction, ceils were 
removed by gentle scraping, collected, and spun at 1,500  rpm for 
5 min. Supernatants were removed by aspiration, and cells were 
lysed by Triton and freeze thawing. Lysates were then used for 
both the luciferase and ~-galactosidase assays. 
Luciferase and ~3-Galactosidase Assays.  Luciferase assay was per- 
formed  in  a  buffer  containing  25  mM  glycylglycine, 15  mM 
MgSO4, and 5 mM ATP. Assay buffer (350  ~1) and 50 ~1 of cell 
lysate were combined before reading in a standard luminometer 
using automated injection of D-luciferin-potassium salt  (#1600; 
Analytical Luminescence Laboratory, San Diego, CA) at a con- 
centration of 0.33 mg/ml. 
[3-Galactosidase  assay was  performed in a buffer containing 1 
mM MgC12, 50 mM 13-ME, 0.88 mg/ml of O-nitrophenyl-13-D- 
galactopyranoside, and 7.4 mM sodium phosphate buffer, pH 7.3. 
The  cell lysate (30  I*1) was incubated with the buffer in a total 
volume of 300 txl for 30 min at 37~  and then inactivated for 10 
rain at 60~  Readings were taken at OD410 in a standard spec- 
trophotometer. 
RNase  Protection and  Northern Blot.  R.Nase  protection  and 
Northern blot analyses and the preparation of the various probes 
used were performed as described (15). 
Nudear  Run-On  Assay.  Isolation of nuclei and in vitro nu- 
clear transcription were performed as described (19, 20). In all ex- 
periments, the coding region of each probe of interest was PCtL 
amplified and spotted on the filter at 200  ng/slot in denatured 
form. 
Cloning of the Human  IL-12 p40 Promoter.  The human IL-12 
p40  promoter  was  identified from  a  k-phage  genomic  clone 
(L26a  obtained from a Lambda Fix Library; Stratagene Inc., La 
Jolla, CA) by screening a PstI digest of this clone subcloned into 
Bluescript KS(-) using as probe an oligonucleotide correspond- 
ing  to  the  first  20  nucleotides  of the  longest  cDNA  clone: 
5'-GCAGAAGAAACAACATCTGT-3'.  A  3.3-kb  fragment 
was  positively identified,  sequenced,  and  cloned  into  the  lu- 
ciferase reporter construct pXP2 (21) at the PstI site. All deletion 
mutant constructs were generated by PCIL and fully sequenced 
for verification. 
Primer Extension.  Total RNA (15 Izg) from Staphylococcus au- 
reus-stimulated  PBMC,  12-0-tetradecanoylphorbol  13-acetate 
(TPA)--stimulated tLPMI-8866  cells,  or  yeast  RNA  (negative 
control) was mixed with an end-labeled antisense primer (25-mer 
corresponding to nucleotides 25-49 in the published p40 cDNA 
sequence  [1]:  5'-GGAAAACCAAGAGATGACCAACTGC-3') 
and  reverse  transcribed.  The  extension products  were  electro- 
phoresed on a 6% denaturing polycrylamide gel (7 M  urea) along 
with size markers (~b ￿  174/HaelII digests). The precise length of 
the  extension  products  was  determined  based  on  M13/mp19 
DNA  sequenced  with  the  universal  primer  and  run  simulta- 
neously. 
Results 
Induction  of IL-12  Protein  Production  in  PBMC.  PBMC 
from four donors were treated with rhIFN-y at 1,000 U/ml 
for 24,  16,  or 8  h  before and simultaneous with  (0 h) LPS 
(1  Ixg/ml) stimulation (30 h).  Supematants were then col- 
lected, and IL-12 p40 and p70 were measured by ILIA and 
ELISA, respectively. As shown in Fig.  1,  IFN-~ alone did 
not induce significant p40  production, whereas LPS alone 
stimulated a modest fivefold increase over that of unstimu- 
lated ceils.  IFN-~/ treatment  followed by LPS  stimulation 
resulted in a dramatic increase in p40 production. The syn- 
ergistic effect peaked at 16 h oflFN-~/pretreatment, with a 
75-fold stimulation in p40 production. Ceils treated simul- 
taneously with  IFN-~/ and  LPS produced only marginally 
more p40 than those stimulated with either IFN-~ or LPS 
alone. The profile of p70 production followed that of p40 
very closely, with a production peak (400 pg/ml) at "~  h 
of IFN-',/ pretreatment.  This represents a  40-fold stimula- 
tion over the unstimulated level, resembling the magnitude 
of the level of induced p40 production. The p40/p70 ratio 
was "-'30:1. 
An alternative approach was  taken to  measure  p40  and 
p70 production by adherent monocytes from a normal do- 
nor  by  immunoprecipitation  with  the  anti-p40  mAb 
C11.79  coupled to CNBr-Sepharose.  Immunoprecipitated 
proteins were analyzed by SDS-PAGE under nonreducing 
conditions  (Fig.  2).  By  this  assay, p40  and  p70  were  de- 
tected  only  in  ceils pretreated with  IFN-  3,  for  24  h  fol- 
lowed  by  18  h  of LPS  stimulation.  The  apparently high 
p70/p40  ratio  on  autoradiography  reflects  the  fivefold 
higher methionine  content of the p35  chain than the p40 
chain  (1),  corresponding  to  a  calculable p70/p40  protein 
ratio of "~  which is within the normal range observed 
using  immunological  assays.  The  identity  of the  slower- 
moving band immunoprecipitated by anti-p40 is not clear 
but  has  been  consistently  observed,  even  with  Chinese 
hamster  ovary  cell-produced  rhlL-12  p40  (not  shown), 
suggesting that it is a more glycosylated form. 
149  Ma et al. Figure  1.  Production  of IL-12 p40  (A) and p70  (B) in PBMC stimu- 
lated with IFN-y and LPS. PBMC from four normal  donors  were cul- 
tured in medium only (no IFN-y) or in the presence  of rhlFN-3,  (1,000 
U/ml) for 24, 16, or 8 h before or simultaneously with (0 h) LPS stimula- 
tion (1  Izg/ml,  24 h).  Control cultures were pretreated  with IFN-'y but 
not stimulated with LPS. IL-12  p40  (RIA detecting  both free and p35- 
bound  forms  of the p40  chain,  A)  or the biologically  active  p70  het- 
erodimer (ELISA, B) were determined  in cell-free supematant  fluids. Re- 
sults are mean •  SE of four donors. 
Induction of  p40 and p35 Steady-State mRNA Accumulation 
and Transcription in PBMC.  Total RNA  was isolated from 
four  PBMC  preparations  treated  with  IFN-y  16  h  before 
LPS  stimulation  (4 h),  and  accumulation  of lL-12 p40  and 
p35  and  ]3-actin  mRNA  was  evaluated by RNase  protec- 
tion assay.  The  4-h  stimulation  time was previously deter- 
mined  as  optimal  for  LPS  stimulation  of the  IL-12  genes, 
Fig.  3  A  shows  results  obtained  with  a  representative  do- 
Figure 2.  Immunoprecipitation  oflL-12 p40 
and  p70  produced  by human  monocytes.  Im- 
munoprecipitation  of  [3SS]methionine-labeled 
IL-12  produced  from  an  enriched  monocyte 
preparation  was carried out as described in Ma- 
terials  and  Methods  using  the  anti-p40  mAb 
Cll.79  coupled  to  CNBr-Sepharose.  Lane  1, 
unstimulated  monocytes;  lane  2,  monocytes 
treated  for 24  h  with rhlFN-',/ (1,000 U/nil); 
lane  3, monocytes  treated  with LPS (1  Ixg/ml) 
for  18  h;  lane  4,  monocytes  pretreated  with 
IFN-y for 24 h before LPS stimulation  (18 h). 
Figure 3.  Accumulation  oflL-12 p40 and p35 mRNA and gene tran- 
scription in human  PBMC. Induction oflL-12 p40 and p35 mRNA ac- 
cumulation  (A) was analyzed in human PBMC treated with IFN-"/ 16 h 
before LPS stimulation  (4 h). mRNA were isolated by RNAzol and sub- 
jected to RNase protection assays using the indicated  riboprobes.  Pro- 
tected fragments were precipitated  and fractionated by PAGE.  Gels were 
dried  and  exposed  to  Phosphorlmager  screens and  quantitated  as  fg of 
specific mRNA per microgram  of total  RNA after normalizing  against 
the [3-actin message. Transcriptional  rate was analyzed by nuclear ran-on 
assays (/3) performed  on isolated nuclei prepared from human PBMC pre- 
treated  with  IFN-'y  for  16  h  followed  by  LPS  stimulation  for  4  h. 
[~x-32p]UTP-labeled nuclear  RNA was  hybridized  for  72  h  to  PCR- 
amplified p40,  p35,  and  ]3-actin cDNAs (coding regions  only,  200  ng/ 
slot) immobilized  on nylon membranes.  The dried membranes were sub- 
jected to  Phosphorlmager  analysis as  described  above.  A  representative 
experiment  is shown out of four performed with similar results. 
nor.  To  determine  the  extent  of p40  and  p35  mRNA  in- 
duction,  nuclear  run-on  experiments  were  performed  in 
isolated  nuclei  prepared  from  PBMC  pretreated  with 
IFN-y  followed by LPS stimulation for 4  h.  Fig. 3  B  shows 
results  of a  representative  experiment.  Analyses  of  tran- 
scription  rate,  steady-state  mRNA  accumulation,  and  p40 
protein  synthesis  from two  to  four donors  are  summarized 
in Fig. 4. 
The  p40  mRNA  was  synergistically induced  by  IFN-~/ 
pretreatment  followed  by  LPS  stimulation,  whereas  p35 
mRNA  was  additively stimulated.  IFN--/alone  only mar- 
ginally  induced  p40  mRNA  but  stimulated  a  twofold  in- 
crease in  the  p35  transcript.  LPS  stimulated  the  accumula- 
tion  of both  transcripts.  The  transcription  rate  of p40  was 
not enhanced by either IFN-y  (16 h)  alone or, in most ex- 
periments,  by  LPS  (4  h).  This  apparently  differs  from  the 
steady-state  mRNA  accumulation,  which  was  stimulated 
10-fold  by  LPS  alone,  and  from  the  level of protein  pro- 
duction,  which  was  stimulated  5.4-fold  (Fig.  4),  perhaps 
because  of a  posttranscriptional  role for LPS  in  stimulating 
p40  gene expression,  although  in other experiments a mar- 
ginal induction oflL-12  p40 gene transcription  by LPS was 
observed  that  might account  for the  enhanced  mRNA  ac- 
cumulation  (results  not  shown).  Pretreatment  with  IFN-y 
for  16  h  before LPS  stimulation  resulted  in a  11.6-fold  in- 
crease  in  p40  gene  transcription,  compared  with  a  24-fold 
increase  in  the  steady-state  mRNA  level,  indicating  that 
the  effect of IFN-y  priming  of LPS-induced  p40  mRNA 
150  Transcriptional Control oflL-12 Genes Figure 4.  Relative induction rates of transcription, steady-state mRNA 
accumulation, and protein secretion for IL-12 p40 and p35. Relative rates 
of transcription, steady-state mRNA accumulation,  and protein produc- 
tion are  shown for  IL-12  p40  and p35  genes  in PBMC  treated  with 
rhlFN-y (1,000 U/n-d, 18 h) or not treated and followed by LPS stimula- 
tion (1 Izg/ml, 4 h for transcription and mRNA analysis,  24 h for protein 
production)  or no stimulation. Values shown for p40 gene expression are 
the mean +  SE of three  to four experiments, and those for p35 are the 
average of two experiments. Because free p35 is not detectable in the su- 
pernatant  fluid, values for the  p70  heterodimers  were  used to  evaluate 
production of the p35 protein. 
Figure 5.  Restriction map (A), determination of transcription start site 
(B), and partial sequence (C) of the human IL-12 p40 promoter.  The hu- 
man IL-12 p40 promoter was identified from a k-phage  genomic clone. 
The restriction map of a fragment containing part of the first intron, the 
first exon,  and ~3.3 kb of the 5' upstream region is shown  in A. The 
transcription  start site was determined  by primer extension  using total 
RNA from S. aureus~timulated PBMC, TPA-treated  RPMI-8866 cells, 
or yeast RNA (B). The sequence of the proximal promoter region of the 
IL-12 p40 gene is shown in C. The putative motifs IRF-1 (47), NF-IL-6 
(48), NFKB (49), SP1  (50), ets  (51), and the TATA box identified by 
computer analysis are underlined and in boldface type. The first exon is 
underlined. The boxed elements, IRF-1, NF-IL-6, ets, and NFKB, were 
functionally analyzed in this study (see Results). 
expression  is exerted  primarily at  the  transcriptional level. 
On the other hand, the transcription rate of p35  enhanced 
by either LPS,  IFN-'y, or both appears  to be primarily re- 
sponsible for  the  accumulation of its  steady-state  mRNA 
because of the close  correlation of the induction rates  ob- 
served at the transcriptional and steady-state mRNA  levels. 
Cloning  of the  Human  IL-12/p40  Promoter.  To  study 
further  the  regulatory  mechanisms  of the  p40  gene,  we 
identified a  3.3-kb  PstI  fragment from  a  X genomic  clone 
(L26).  Primer  extension  using total  RNA  obtained  from 
RPMI-8866  cells  or  S.  aureus-stimulated  PBMC  and  an 
antisense primer (25-mer, corresponding to nucleotide po- 
sitions  25-49  in  the  p40  cDNA  clone  [1])  revealed  two 
major extension products of 91  and 92 bp, respectively, al- 
lowing placement of the transcription initiation site for the 
p40 gene near the 3' end of the 3.3-kb PstI genomic frag- 
ment (Fig.  5,  A  and B).  The 91-bp product may have de- 
rived from  an incomplete  extension because  of difficulties 
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encountered by reverse transcriptase in proceeding through 
the methylated  cap  site. A  2-kb sequence upstream of the 
cap  site was determined,  and Fig.  5  C  shows the proximal 
promoter  sequence.  This  promoter  (from  +56  to  the  5' 
end of the 3.3-kb clone) was linked to a  fruit fly luciferase 
reporter  gene  (pXP2;  21)  and used  for  transient transfec- 
tions  in a  number of myeloid  and lymphocytic  cell lines. 
The 3.3-kb promoter was found to be constitutively active 
in the RPMI-8866  and CESS B  cell lines, and, unlike the 
endogenous  gene  in  these  cells,  did  not respond  to  TPA 
stimulation. The promoter was inducible by LPS in THP-1 
(human macrophagic)  cells and RAW264.7  (murine mac- 
rophagic)  cells,  but inactive in Jurkat  and Molt-13  T  cell 
lines (Fig.  6),  suggesting that  the  cloned promoter  region 
contains adequate sequence information for appropriate cell 
type-specific expression (Fig. 6). 
Induction of  p40 Steady-State  mRNA and Transcription Rate 
in the Murine Macrophagic Cell Line RAW264.7.  To study Figure  6.  Transfection of B,  T,  and  monocytic  cell 
lines. CESS, RPMI-8866  (both EBV  + human B lympho- 
blastoid cell lines), Molt-13, andJurkat (both human T cell 
lines) were transfected  by electroporation, and THP-1  (hu- 
man  monocytic  cell  line) by  DEAE-dextran  with  the 
3.3-kb  IL-12 p40 promoter-luciferase construct or other 
constructs. At 18 h after transfection, cells were cultured in 
medium or treated with TPA (20 ng/ml,  15 h) or LPS (1 
btg/ml, 8 h) as indicated. Luciferase  activity was measured 
in the cell lysate, and values were normalized against the 
internal control (CMV-[3-galactosidase  construct). Expres- 
sion vectors: p40-luc, the 3.3-kb p40 promoter  linked to 
the luciferase  reporter; pXP2, luciferase reporter without a 
promoter;  RSV-luc, a  luciferase reporter  driven  by  the 
RSV promoter. 
the regulation oflL-12 expression at the molecular level, an 
in vitro system was established using the murine RAW264.7 
cell line because of its monocytic origin, its ability to pro- 
duce physiologically relevant levels of IL-12 in response to 
LPS  and  IFN-"/  stimulation,  and  its  ready amenability to 
transfection.  Steady-state  p40  mRNA  accumulation  was 
determined by Northern  blot analysis in  total RNA  sam- 
ples  isolated from  cultured  RAW264.7  cells  treated  with 
rmlFN-'y (1,000 U/rnl) for 16 h  before LPS stimulation (1 
txg/ml, 8 h). As shown in Fig. 7 A, neither LPS nor IFN-3' 
alone had any significant effect on p40  mRNA  accumula- 
tion,  whereas a  synergistic stimulatory effect was observed 
when  LPS  was  added  after  the  IFN-',/  pretreatment  of 
RAW264.7  cells. IFN-y pretreatment  (16 h)  or LPS  (8 h) 
had little effect on IL-12 p40 gene transcription as analyzed 
by nuclear run-on experiments (Fig. 7  B), whereas the syn- 
ergy between IFN-y and LPS in inducing transcription was 
very pronounced and might account for the increase in the 
level of steady-state p40 mRNA. 
IFN-  T  Primes for  LPS  Induction of the  p40  Promoter in 
RA W264.7 Cells.  RAW264.7 cells were transfected with 
Figure  7.  IL-12 p40 mRNA accumulation and transcription induced 
by IFN-y and LPS in RAW264.7 murine macrophagic cells. Total RNA 
was isolated from RAW264.7  cells treated with medium alone, IFN-y 
(1,000 U/n-d, 16 h), LPS (1 btg/ml, 8 h), or pretreated with IFN-y (16 h) 
followed by LPS stimulation (8 h). Northern blot (15 p.g RNA) and hy- 
bridization (A) were performed in 50% formamide at 42~  for 18 h, using 
a murine p40 cDNA probe. The filter was stripped and reprobed with a 
murine 13-actin  probe. Transcription rate was determined by nuclear run- 
on experiments (B) performed with isolated nuclei from RAW264.7 cells 
treated  as  indicated  above.  Labeled nuclear  RNA  was  hybridized to 
membrane-immobilized murine p40, p35, and [3-actin cDNAs (coding 
regions only) amplified by PCR  (200 ng/slot).  The  figure shows the 
Phosphorlmager results of one of two experiments with identical results. 
the 3.3-kb p40 promoter-luciferase construct by electropo- 
ration and pretreated with IFN-~, (1,000  U/ml)  for differ- 
ent times, as indicated in Fig. 8 A, followed by LPS stimu- 
lation  (1  btg/ml).  Luciferase activity was  measured  in  cell 
lysates prepared from cells collected 8  h  after LPS stimula- 
tion,  and  the  values  were  normalized against  the  internal 
control  ([3-galactosidase)  to  correct  for  transfection  effi- 
ciencies. Treatment with IFN-y alone did not stimulate the 
promoter,  whereas  LPS  increased  the  promoter  activity 
~'-,4.5-fold.  However,  pretreatment  of  RAW264.7  cells 
with IFN-y for 8 h  before LPS stimulation had the greatest 
synergistic effect on  the promoter,  inducing a  30-fold in- 
crease of activity. The  magnitude of this effect was similar 
to the effect of those stimuli on the transcription of the en- 
dogenous p40  gene  (Fig. 7  B).  In addition, the kinetics of 
the priming effect oflFN-y  was analogous to that observed 
for production of the endogenous p40 protein under iden- 
tical culture conditions (Fig.  8  B),  and also similar to  that 
observed for  production  of the  p40  protein  from  human 
PBMC  (Fig.  1 A). The maximum induction in both types 
of cells was ~-,75-fold, although  the  IFN-y-priming effect 
in RAW264.7  cells appears to be more swift but transient 
than in PBMC. 
5'  deletion mutants  of the p40 promoter were tested in 
RAW264.7  cells for their ability to induce transcription of 
the reporter-luciferase gene in response to LPS and IFN-y 
(Fig. 9).  When  truncated at  -222,  the p40  promoter was 
still induced synergistically  by the two stimuli, although at a 
level  ~50%  of the  3.3-kb  construct,  indicating  that  up- 
stream  elements  exist  that  enhance  transcription.  Further 
deletion of the  promoter  to  -204  drastically diminished, 
but  did  not  completely  eliminate,  the  inducibility  by 
IFN-y and LPS. A  potential ets motif, TTTCCT  (or AG- 
GAAA for the complement), is located between  -204  and 
-222.  A  5-bp  deletion  that  eliminated  the  TTTCC  se- 
quence  in  the  context  of the  3.3-kb  promoter resulted in 
almost complete unresponsiveness to IFN-y and LPS  (Fig. 
10). When a CMV-based murine ets-2 expression vector (a 
gift from Dr.  R.  Maki) was cotransfected into  RAW  cells 
with  the  wild-type or the  deletion mutant,  the  wild-type 
construct was  activated in all four conditions by ets-2 but 
not by ets-1, PU-1, or the control vector (data not shown), 
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Figure 9.  Activation by IFN-"/and LPS of 5' deletion mutants of the 
human  IL-12  p40-1uciferase constructs  transfected  in  RAW264.7  cell 
lines. RAW264.7 cells were transfected by electroporation  with the indi- 
cated 5' deletion mutants and stimulated with IFN-~ (8 h pretreatment) 
and LPS (8 h) as described in Fig. 8. The results presented (luciferase ac- 
tivity  normalized  against an  internal  cotransfected  [~-galactosidase stan- 
dard) are mean "4- SD from six independent experiments. All values were 
then normalized against the medium condition of the -3,300 construct 
which was taken as 1. 
Figure 8.  IFN-~ primes the transfected human IL-12 p40 promoter in 
the nmrine RAW264.7  monocytic cell line  for activation  by LPS  (A) 
with a similar kinetics and potency to those of the endogenous murine 
p40 production (B). ILAW264.7  cells were transfected with the 3.3-kb 
p40 promoter-luciferase  construct by electroporation.  At 16 h after trans- 
fection, cells  (5 ￿  106 cells/well per 2 ml) were treated with 1.2% DMSO 
for 24  h  before LPS  stimulation.  Cells were pretreated  with rmlFN-"/ 
(1,000 U/ml) for 24, 16, 8, and 0 h before the addition of  LPS (1 p~g/ml, 
8 h). Cell lysates were used for both the luciferase assay and J3-galactosi- 
dase assay. All luciferase values were then corrected against those of their 
respective [3-galactosidase  values. The results are representative of two ex- 
periments  of kinetics  of IFN-~/ pretreatment and  of at least 10  experi- 
ments using either 8- or 18-h  pretreatment with IFN-y. To detemliue 
secretion of the endogenous murine IL-12 p40 protein,  RAW264.7 cells 
were cultured  at 106/ml in 1 ml of medium and treated as above except 
that LPS stimulation was for 24 h; IL-12 p40 in the cell-free culture su- 
pernatants was determined by ILIA. All samples were cultured  in dupli- 
cate, and each duplicate culture was evaluated by RIA in triplicate wells. 
Mean values are presented with SE. 
whereas ets-2 did not induce the deletion mutant, suggest- 
ing that the action of ets-2 was indeed mediated by this el- 
ement. 
The  -222  construct, although active in both monocytic 
and  B  cells,  was  silent when  transfected into  T  cell  lines 
(data not shown), indicating that it is still regulated in a tis- 
sue-specific manner like the 3.3 kb promoter. 
The  -204  construct was noticed to maintain a  low but 
consistent inducibility by IFN-y  and LPS.  A  possible can- 
didate responsible for this low level of induction is NFKB, 
which indeed binds to a  consensus site located at  -116  to 
-  107  (CCCTTAAAGT  or GGGAATTTTA  for the com- 
plement) in response to LPS stimulation in the form of p50 
homodimer  primarily,  but  also  of p65/C-rel  heterodimer 
and  C-rel  homodimer  (data  not  shown).  However,  the 
functional role of this site remains to be established. 
Two  other upstream elements, that is, IRF-1, located at 
-730  to  -719,  and NF-IL6, at  -520  to  -512,  were also 
examined  by  deleting  the  individual  elements  from  the 
3.3-kb promoter. In both cases, no loss of responsiveness to 
IFN-~/and LPS was observed (data not shown). 
Discussion 
In  this  report,  we  show  that  the  IL-12  p40  and  p35 
genes are regulated primarily at the transcriptional level in 
response to IFN-~  and LPS stimulation in human PBMC. 
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Figure  10.  Activation  of  the  IL-12  p40  promoter  by  ets-2  in 
P,.AW264.7 cells. RAW 264.7 cells were transfected by electroporation 
with the 3.3-kb  promoter construct  or the same construct  with a 5-bp 
deletion  at the ets site. A murine ets-2  expression vector driven by the 
CMV enhancer/promoter was cotransfected at a molar ratio of 1:1  (re- 
porter/effector).  The wild-type and mutant sequences around the ets site 
are  shown.  All  values were  relative  to  the  medium  condition of the 
-3,300 construct, which was set at 1. 
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duction.  This  finding  confirms  our  previous  results  (13, 
16),  but  contrasts with  those  of Yoshida  et al.  (22),  who 
detected  a  marked  increase  in  p40  mRNA  levels  in  the 
murine  macrophage cell  line J774  when  stimulated  with 
IFN-',/alone. We have been unable to confirm this obser- 
vation in PBMC or in the murine macrophage-derived cell 
line RAW264.7.  One explanation for the different obser- 
vations  might  rest  in  the  use  of  culture  media  in  the 
Yoshida  et al.  (22)  study that might not have been endo- 
toxin free. Unlike IFN-y, LPS alone induced a 10-fold in- 
crease in p40 mRNA and a fivefold enhancement in p40 
protein  production,  although  minimal  transcriptional  up- 
regulation was observed, suggesting that the effects of LPS 
stimulation could be in part posttranscriptional,  for exam- 
ple, at the level of mRNA stability. Direct confirmation of 
this mechanism is difficult because the unstimulated level of 
p40 message is too low to quantitate its half-life. 
Priming of PBMC with IFN-y for 16-24 h followed by 
LPS  stimulation  (8  h)  increased the  expression synergisti- 
cally with an 11.6-fold enhancement in transcription rate, a 
24-fold stimulation in mRNA accumulation, a 75-fotd in- 
duction in the level of secreted p40 chain (both in the free 
and the heterodimeric forms), and a 40-fold increase in p70 
heterodimer production.  The varying degrees of enhance- 
ment of p40  transcription,  mRNA,  and protein might be 
attributed to posttranscription/translational control mecha- 
nisms.  However,  because  nuclear  run-on  assays  measure 
the transcriptional rate at a specific time, RNase protection 
measures the steady-state levels of stable mRNA accumula- 
tion,  and protein  determination  assays measure  the  accu- 
mulation  of a  stable product in  the  supernatant  fluid,  the 
difference in the degrees of enhancement might simply re- 
flect the detection methods and/or differences in kinetics. 
Thus, our results point strongly to a transcriptional control 
of p40  gene  expression  in  response  to  LPS  after  IFN-y 
priming. The level of p35 mRNA also appears to be regu- 
lated primarily transcriptionally, since there is a good corre- 
lation  between  changes  in  transcription  rate  and  steady- 
state  mRNA  accumulation.  IFN-y and  LPS  each  induce 
IL-12 p35 gene transcription and mRNA accumulation. In 
addition,  an additive  effect on p35  gene transcription  and 
mRNA  accumulation  is  observed in  PBMC  treated with 
both IFN-y and LPS. The net result of transcriptional up- 
regulation of both the p40 and the p35 gene is an observed 
increase  in  the  production  of the  biologically active  p70 
heterodimer. The marked increase in p70 protein is, how- 
ever, difficult to reconcile with the modest increase in p35 
transcripts in response to IFN-y and LPS. This discrepancy 
may indicate  translational/posttranslational  mechanisms or 
may be due to the constitutive expression of the p35 gene 
in cell types within the PBMC preparation that do not pro- 
duce IL-12. 
The cloned 3.3-kb  p40 promoter transfected in several 
human and murine cell lines with a construct with the lu- 
ciferase reporter gene showed both cell type specificity and 
responsiveness to IFN-~/and LPS, analogous to the endog- 
enous gene, suggesting that it may contain sufficient cis ele- 
ments to elicit cognate responses to specific stimulation. 5' 
promoter deletion  analysis  strongly implicated  the  region 
between  -222  and  -204,  which  includes  a  putative  ets 
motif. This region is responsive to IFN-~/and LPS stimula- 
tion. Deletion of the ets motif in the context of the entire 
3.3-kb promoter resulted in the loss of its responsiveness to 
both IFN-y and LPS,  as well as to activation by cotrans- 
fected  ets-2,  strongly suggesting  the  critical  role  that  this 
site  may play  in  the  induction  of the  p40  promoter  by 
IFN-~/and LPS. However, ets-2 may not be the only fac- 
tor  required  to  activate  the  promoter,  since  the  cotrans- 
fected ets-2 failed to activate the promoter in unstimulated 
cells  to the level of IFN-y- and LPS-stimulated cells,  but 
synergized with IFN-~/and LPS in inducing promoter acti- 
vation.  Our  unpublished  preliminary observations suggest 
that the -222/-204  and the extended region up to -292 
interacts with a series of nuclear factors including ets-2 that 
responds  to  IFN-y and  LPS  stimulation  differentially and 
may control the regulation of the promoter in a complex 
manner. 
Analysis of p40 promoter regulation in the  easily trans- 
fected cell line RAW264.7  showed that, as in PBMC, the 
induction  of p40 mRNA is primarily transcriptional since 
the  increase  in  stimulated  p40  transcription  is  in  accord 
with the increase in its  steady-state mRNA accumulation. 
Like PBMC,  these cells are primed by IFN-y for produc- 
tion of p40 in response to LPS, indicating the suitability of 
this cell line as an in vitro system to study IL-12 gene regu- 
lation. The data obtained on the expression of the endoge- 
nous p40 gene and the activation of the transfected cloned 
human p40 promoter using the RAW264.7  homogeneous 
monocytic cell population as well as PBMC  strongly sup- 
port  the  notion  that  IFN-y and  LPS  act  directly on  the 
IL-12-producing cells.  This  conclusion  is supported by a 
recent report by Hayes et al.  (23)  using elutriated  mono- 
cytes,  which  responded  to  IFN-y treatment  followed  by 
LPS stimulation in producing IL-12 p40 message and pro- 
tein synergistically. 
Priming/enhancing  effects of IFN-y on  the  expression 
of several other inflammatory cytokines secreted by mono- 
cytes/macrophages in response to LPS stimulation,  that is, 
IL-1, IL-6, TNF-ci, and G-CSF, have been described (24- 
30).  This priming is not only efficient but also assumes par- 
ticular physiological relevance in the case of IL-12, because 
IL-12 itself is a potent inducer oflFN-y production (1, 31, 
32).  Thus, after an infective or inflammatory stimulus that 
provokes  IL-12  production,  IL-12-induced  IFN-2r  may 
enhance  the  ability  of the  phagocytic  cells  to  produce 
IL-12 and other proinflammatory cytokines with a power- 
ful  positive  feedback mechanism.  Self-enhancing  mecha- 
nisms  of proinflammatory  cytokine  production  must  be 
effectively regulated to avoid pathological effects;  the pro- 
duction of factors such as IL-10, IL-4, IL-13, TGF-[3, and 
PGE2, which have been described to inhibit IL-12 produc- 
tion and/or to inhibit  IL-12 activity on lymphocytes (15, 
17,  33),  is probably responsible for the  negative feedback 
regulation  of the  IL-12/IFN-3, loop.  Even  in  the  almost 
uncontrolled  induction  of  inflammatory  cytokines  ob- 
154  Transcriptional Control of IL-12 Genes served in LPS-induced shock, these regulatory mechanisms 
appear  to  be  effective, because  the  production  of IL-12 
subsides  before the peak of IFN-',/ production is observed 
at 5-7 h after LPS injection, and anti-IFN-~t antibodies do 
not prevent the LPS-induced production of IL-12 in vivo 
(18).  However,  in  the  Shwartzman-like  reaction  in  the 
mouse, the  IL-12-induced IFN-~  production in response 
to  a  local low-dose priming  injection  of LPS  appears  to 
play an important role in priming the phagocytic cells for 
production of IL-12 and other proinflammatory cytokines 
in response to the challenging dose of LPS (34).  Further- 
more, in response to infectious agents with limited ability 
to  induce  IL-12  production,  for  example,  mycobacteria, 
the priming effect of IFN-y appears to be required for op- 
timal production of IL-12 both in vitro and in vivo. 
The central role of IFN-',/ priming in the physiological 
regulation of IL-12 activity during inflammation and im- 
mune response underlines the importance of understanding 
the  molecular mechanisms of such priming.  Interestingly, 
different mechanisms have been found to be responsible for 
the priming/enhancing effect of IFN-'y on the expression 
of genes other than IL-12, including proinflammatory cy- 
tokines and the nitric oxide (NO) synthase gene in phago- 
cytic cells. In the case of G-CSF, it was shown that IFN-'y 
enhances  LPS-induced  transcription  and  stabilizes  LPS- 
induced  mRNA  (30).  IFN-y  also  primes  for  enhanced 
transcription of the IL-6 gene induced by LPS or TNF-o~ 
(35,  36).  The  regulation  of the  NO  synthase  gene  by 
IFN-y and LPS is particularly complex (37-41). Unlike the 
p40 gene, transcription of the NO synthase gene is induced 
by either IFN-2t or LPS, with  the  two inducers together 
showing a modest synergistic transcriptional effect in some 
studies (39, 40) but not others (41). Two upstream regions 
in  NO  synthase  promoters  appear  to  be  responsible  for 
induction  by  IFN-'y  and  LPS,  involving binding  of the 
IFN-regulatory factor (IRF-1)  and the  NF-KB/Rel tran- 
scription factor, respectively (38-40). 
Our results  suggest that the priming effect of IFN-',/ on 
IL-12 production is due mostly to an enhancement of the 
ability of LPS to induce transcription of the p40 gene. Al- 
though, unlike the p40 gene, IFN-y alone was shown to 
induce transcription of the p35 gene, simultaneous stimula- 
tion with both IFN-y and LPS was  required for maximal 
expression of the p35  gene and secretion of the p40/p35 
biologically active heterodimer. Our observations raise  the 
possibility that  discrete cis  elements exist in  the p40  pro- 
moter that respond to IFN-',/and LPS separately and coop- 
eratively. The region -222 to  -204 in the p40 promoter 
appears to be responsible for both LPS responsiveness and 
IFN-y priming. A perfect IR.F-l-binding site is present in 
the p40 promoter at  -730 to  -719; however, this is up- 
stream of the region required for IFN-~/priming, thus sug- 
gesting that,  unlike in the NO synthase gene (39),  IKF-1 
may not be responsible for activation of the p40 promoter. 
Deletion of 5 bp within the element from the 3.3-kb pro- 
moter  did  not  decrease  responsiveness  to  IFN-y  (not 
shown),  confirming the lack of activity of the IRF-1  ele- 
ment. An NFKB element is present at  -116  to  -107.  It 
was  found to  bind  primarily the  NFKB p50  homodimer 
and, to a lesser extent, interact with p65/C-rel heterodimer 
as well as C-tel homodimer in response to LPS stimulation. 
However, the functional significance of this element awaits 
confirmation. 
IFN-~/ pretreatment of cells may induce factors that by 
themselves do not stimulate the p40 promoter but interact 
with LPS-induced factors, resulting in the activation of the 
promoter. The fact that a long preincubation period with 
IFN-~/(16 h in PBMC, 8 h in RAW264.7 cells) is required 
to maximize LPS-stimulated IL-12 p40 expression suggests 
that the effects of IFN-'y priming might not be direct, such 
as  those  observed  in  some  immediate-to-early  response 
genes,  for example,  IL-I~,  TNF-oL, and  IL-6.  This late- 
acting effect and the absence of clearly identifiable IFN-~/ 
activation sequences (GAS)  in the proximal p40 promoter 
make a role for the JAK-STAT-GAS signal  transduction 
pathway (42)  in  IL-12 expression unlikely. However, the 
possibility cannot be ruled out that the initial signal  trans- 
duction events involve the JAK-STAT pathway, leading to 
the expression of gene products that are indirectly responsi- 
ble for the upregulation of IL-12 gene transcription.  The 
-292 to -204 region of the p40 promoter contains several 
consensus elements for binding of nuclear factors, as identi- 
fied by a  computer search.  Particularly interesting are  an 
activator protein 1 (AP1) and an ets element, ets family fac- 
tors have been shown to be important for transcriptional 
regulation  of other cytokines  (e.g.,  PU-1  for IL-I~  [43] 
and  ets-1  for TNF-ci  [44]),  in  some  cases  forming com- 
plexes with APl-related factors (44).  Some ets family fac- 
tors are also known to be preferentially expressed in phago- 
cytic cells and B cells (45), the cell types expressing the IL- 
12 p40  gene. The p40 3.3-kb upstream promoter, analo- 
gous to the endogenous p40 gene, is constitutively active in 
B lymphoblastoid cell lines and inducible in monocytic cell 
lines but not in T  cell lines.  Thus,  analysis  of the cis  and 
trans  elements in the p40 promoter should provide infor- 
mation on the control of cell specificity and regulation of 
expression in  monocytic and B  cells  of one of the  genes 
controlling the production of IL-12, a cytokine that plays 
an  important  role in  inflammation  and  regulation  of the 
immune response. This knowledge is also important for the 
understanding of the mechanism underlying the profound 
depression of IL-12 p40  and p70 production observed in 
HIV-infected  individuals  (46),  which  may  contribute  to 
the immunodeficiency in AIDS patients. 
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